首页> Cancer discovery> Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.

Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.

导出 OA

翻译打印收藏纠错

第一作者： Leonie,Smeenk

第一单位： Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.;Oncode Institute, Utrecht, the Netherlands.

作者： Leonie,Smeenk ^[1] ; Sophie,Ottema ^[1] ; Roger,Mulet-Lazaro ^[1] ; Anja,Ebert ^[2] ; Marije,Havermans ^[1] ; Andrea Arricibita,Varea ^[1] ; Michaela,Fellner ^[2] ; Dorien,Pastoors ^[1] ; Stanley,van Herk ^[1] ; Claudia,Erpelinck-Verschueren ^[1] ; Tim,Grob ^[3] ; Remco M,Hoogenboezem ^[3] ; François G,Kavelaars ^[3] ; Daniel R,Matson ^[4] ; Emery H,Bresnick ^[4] ; Eric M,Bindels ^[3] ; Alex,Kentsis ^[5] ; Johannes,Zuber ^[6] ; Ruud,Delwel ^[7]

作者单位： Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.;Oncode Institute, Utrecht, the Netherlands. ^[1] Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria. ^[2] Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. ^[3] Department of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin. ^[4] Tow Center for Developmental Oncology, Sloan Kettering Institute, Department of Pediatrics, Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, New York. ^[5] Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.;Medical University of Vienna, Vienna BioCenter (VBC), Vienna, Austria. ^[6] Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. h.delwel@erasmusmc.nl.;Oncode Institute, Utrecht, the Netherlands. ^[7]